Clinical trials: Risperidone, completed
Schizophrenia
Ginkgo Biloba Extract for Schizophrenia
A double-blind, randomized, placebo-controlled trial of ginkgo biloba extract (Egb-761) as an add-on therapy to risperidone compared to risperidone plus placebo in the treatment of 200 treatment-naive first-episode patients with…
- Trial name
- NCT01524380
- Testing
- Ginkgo biloba extract
- Where
- China
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Beijing HuiLongGuan Hospital
Schizophrenia
Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia
We wanted to compare dopamine D2 receptor activity, brain structure, brain function, sensory gating and cognition in neuroleptic-naive schizophrenic patients and matched healthy controls.
- Trial name
- NCT00206960
- Testing
- zuclopenthixol, risperidone
- Where
- 6 sites in Denmark
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Birte Glenthoj
Schizophrenia, Cognitive and Executive Dysfunction
A Pilot Study of Adjunctive Structured Supportive Psychotherapy in Schizophrenia
This pilot randomized controlled trial examined whether adding structured supportive psychotherapy to risperidone treatment is more effective than risperidone alone in improving cognitive function and reducing peripheral…
- Conditions
- Schizophrenia, Cognitive and Executive Dysfunction, Neuroinflammation
- Trial name
- PILOT-SSP-SCZ (NCT07671040)
- Testing
- Structured supportive psychotherapy, Risperidone, Unstructured Supportive Conversation
- Where
- Indonesia
- Volunteers
- 44 people
- Sponsor
- Hasanuddin University
Psychotic Disorders
Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting
Despite different pharmacological properties, the scientific evidence is inconclusive regarding which of the first-line second generation antipsychotics (SGAs) should be preferred for the individual patient suffering from…
- Trial name
- BPP (NCT00932529)
- Testing
- Olanzapine, Quetiapine, Risperidone
- Where
- Norway
- Volunteers
- 226 people
- Sponsor
- University of Bergen
Schizophrenia, Schizoaffective Disorder
A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
This Phase IV, randomized, parallel-group study is designed to evaluate the cataractogenic potential of quetiapine fumarate (SEROQUEL) compared with that of a putative non-cataractogenic antipsychotic medication risperidone…
- Trial name
- NCT00206102
- Testing
- quetiapine fumarate, risperidone
- Where
- 63 sites in United States
- Volunteers
- 1,098 people
- Sponsor
- AstraZeneca
Schizophrenia, Undifferentiated Type
Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients
After an initial screening visit, including an assessment of psychiatric disorders, patients stabilized on antipsychotic medication (aripiprazole or risperidone) for at least 6 weeks and control subjects will undergo an…
- Trial name
- NCT01109147
- Testing
- Imagery, pharmacogenetic sampling
- Where
- 2 sites in France
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Qualissima
Dementia, Alzheimer Disease
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia
The purpose of the study is to compare the effectiveness of an oral formulation of risperidone (an antipsychotic medication) to that of placebo for treating behavioral and psychological signs and symptoms in dementia (BPSSD)…
- Conditions
- Dementia, Alzheimer Disease, Vascular Dementia
- Trial name
- NCT00249158
- Testing
- Risperidone
- Volunteers
- 344 people
- Sponsor
- Janssen-Cilag Pty Ltd
Schizophrenia
Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients
The purpose of this study is to test the safety and effectiveness of talnetant vs. risperidone vs. placebo in reducing positive and negative symptoms in acutely psychotic schizophrenia patients.
- Trial name
- NCT00300963
- Testing
- Talnetant
- Where
- 20 sites in United States
- Volunteers
- 275 people
- Sponsor
- GlaxoSmithKline
Schizophrenia
Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients
This study will compare employment support with behavioral skills training to employment support alone in schizophrenia patients taking either risperidone or olanzapine to determine which is more effective in helping the patients…
- Trial name
- NCT00183625
- Testing
- Individual Placement and Support (Supported Employment), Social Skills Training, Olanzapine
- Where
- 2 sites in United States
- Volunteers
- 107 people
- Sponsor
- University of California, Los Angeles
Schizophrenia, Psychotic Disorders
A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
The purpose of the study is to show that risperidone (an antipsychotic medication) combined with lorazepam (an anti-anxiety medication) is more effective than conventional therapy administered by intramuscular injection for…
- Conditions
- Schizophrenia, Psychotic Disorders, Emergency Treatment
- Trial name
- NCT00249171
- Testing
- risperidone
- Volunteers
- 226 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Patients Already Taking Risperidone for Clinical Indications
Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva
The purpose of this research is to: (1) examine the secrection of risperidone (RIS) (Risperdal) and its metabolite, 9-OH-RIS, in saliva, (2) determine the concentration ratio of RIS and 9-OH-RIS between plasma and saliva, and (3)…
- Trial name
- NCT00395499
- Testing
- Risperidone
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Ohio State University
Schizophrenia
The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia
A randomized, double-blind trial of the treatment effect of dose-low antipsychotics combined with low-dose sertraline in 1640 schizophrenia patients
- Trial name
- NCT04076371
- Testing
- olanzapine-sertraline combination, only olanzapine, risperidone-sertraline combination
- Volunteers
- 1,640 people
- Sponsor
- Beijing HuiLongGuan Hospital
Bipolar Disorder
A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.
The purpose of this study is to examine the safety and effectiveness of the long acting injectable form of the atypical antipsychotic Risperidone (Risperdal CONSTA), along with treatment as usual (TAU), in bipolar disorder…
- Trial name
- NCT00094926
- Testing
- Risperdal Consta
- Volunteers
- 275 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
- Trial name
- NCT00325689
- Testing
- Quetiapine or Risperidone + Aripiprazole
- Where
- 48 sites in United States
- Volunteers
- 323 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Psychotic Disorders
A Registry of Treatment Adherence for Patients With Schizophrenia
The purpose of the study is to assess demographic, treatment, and outcome data in schizophrenia patients receiving treatment with long-acting injectable, tablet, or liquid formulations of first generation (conventional) or second…
- Trial name
- NCT00283517
- Testing
- antipsychotics
- Volunteers
- 2,046 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia
A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia
The purpose of this study is to compare the effectiveness and safety over 1 year of treatment of intramuscular injections of paliperidone palmitate and long-acting risperidone in patients with schizophrenia.
- Trial name
- NCT00210717
- Testing
- paliperidone palmitate
- Volunteers
- 748 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Tranquilizing Agents
A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)
This study is a non-interventional web based registry designed to assess demographic, treatment and outcomes data in patients receiving treatment with long-acting injectable risperidone.
- Conditions
- Schizophrenia, Tranquilizing Agents, Mental Disorders, Therapeutic Uses
- Trial name
- NCT00294008
- Testing
- Risperdal Consta
- Volunteers
- 230 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia
Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia
The purpose of this study is to assess the 14-day and 12-week safety and efficacy of Depakote ER used in combination with either olanzapine or risperidone versus antipsychotic monotherapy with olanzapine or risperidone for the…
- Trial name
- NCT00073164
- Testing
- Divalproex Sodium Extended-Release Tablets, Olanzapine, Risperidone
- Where
- 35 sites in United States
- Volunteers
- 400 people
- Sponsor
- Abbott
Schizophrenia, Schizoaffective Disorder
Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths
This clinical trial is designed to evaluate different dosages of risperidone ISM, a new long-acting injectable form.
- Trial name
- PRISMA-1 (NCT01788774)
- Testing
- Risperidone ISM 50 mg, Risperidone ISM 75 mg, Risperidone ISM 100 mg
- Where
- 5 sites in Croatia, Russia and 2 more
- Volunteers
- 36 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Major Depression
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism
Reduction of volume of the hippocampus has been associated with major depression in many studies. It has been suggested that antidepressants may protect against hippocampus volume loss in humans associated with multiple episodes…
- Trial name
- NCT00704860
- Testing
- Open label pharmacotherapy
- Where
- Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Ottawa